Abstract:Background: Colorectal cancer (CRC) is one of the most commonly diagnosed and deadly malignant tumors globally, and its occurrence and progression are closely related to the heterogeneity of poor histological features and molecular characteristics among patients.Methods: Comprehensive experiments were performed to validate the role of xCT expression in CRC tumorigenesis and stemness. Bioinformatic analysis and luciferase assays were used to identify upstream transcription factors of SLC7A11. RNA sequencing, Western blotting, and immunofluorescence assays were used to explore the potential mechanisms of xCT in CRC. A rescue assay confirmed the role of MELK in E2F1/xCT-mediated tumorigenesis and stemness in CRC.Results: xCT knockdown significantly suppressed the proliferation, migration and stemness of CRC cells in vitro and effectively inhibited CRC tumorigenesis and metastasis in vivo. E2F1 was identified as a critical upstream transcription factor of xCT that facilitated CRC progression and cell stemness. MELK was confirmed to directly co-expressed with xCT in CRC cells, and its upregulation significantly attenuated xCT knockdown-induced suppression of tumorigenesis and stemness in CRC cells. Further molecular mechanism exploration confirmed that xCT knockdown may exert an antitumor effect by controlling the activation of MELK-mediated Akt/mTOR signaling. Erastin, a specific inhibitor of xCT, was also proven to effectively inhibit CRC tumorigenesis and cell stemness.Conclusion: Altogether, our study showed that E2F1/xCT is a promising therapeutic target of CRC that promotes tumorigenesis and cell stemness. Erastin is also an effective antitumoral agent for CRC.Funding: This study was supported by the National Key Research and Development projects intergovernmental cooperation in science and technology of China (2018YFE0126900), and The Key Research and development Project of Zhejiang Province (No. 2020ZJZC03), The Medical and Health Science and Technology Project of Zhejiang Province (Nos. 2020RC042, 2020KY380 and 2020KY1085).Declaration of Interest: None to declare. Ethical Approval: All experiments involving animals were conducted according to the ethical policies and procedures approved by Experimental Animal Welfare Ethics Review Committee of Zhejiang University, China.

E2F1/xCT-Mediated Augmentation of the Oncogene MELK Maintains Colorectal Cancer Cell Stemness and Facilitates Tumorigenesis